CStone Pharmaceuticals (2616.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Jianxin Yang
Listed since: Feb 26, 2019
Employees: 136

Market position

Day range

Current HK$5.41

HK$5.405HK$5.75

52-week range

Current HK$5.41

HK$4.01HK$13.15

Open: HK$5.59
Previous close: HK$5.385
Volume: 3.15M; 0.32× average
Average volume: 9.89M; Average daily volume
Market cap: 8.65B HKD
Beta: 0.25; Market reference 1
50-day average: HK$4.9421; +9.47% above average
200-day average: HK$6.3024; -14.16% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 6.17B CNY
P/E (TTM): -22.08×
P/B (TTM): 10.99×
P/S (TTM): 30.28×
EV / EBITDA: -15.27×
Earnings yield: -6.65%
Free cash flow yield: -4.99%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 39.88%
Operating margin: -120.09%
Net margin: -123.30%
Return on equity: -70.82%
Return on assets: -32.16%
Return on invested capital: -41.59%

Financial health

Debt / equity: 0.57×
Current ratio: 2.18×
Altman Z-score: -3.87
Piotroski F-score: 2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

269.58M CNY-33.80%

Operating income

−432.62M CNY-371.82%

Net income

−437M CNY-379.13%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	269.58M CNY	407.21M CNY	463.84M CNY	481.36M CNY	243.72M CNY
Cost of goods sold	218.34M CNY	167.05M CNY	159.55M CNY	202.99M CNY	106.83M CNY
Gross profit	51.25M CNY	240.15M CNY	304.3M CNY	278.38M CNY	136.89M CNY
Research and development	311.5M CNY	134.66M CNY	527.8M CNY	614.16M CNY	1.3B CNY
Selling, general, and administrative	172.36M CNY	166.94M CNY	248.07M CNY	390.48M CNY	472.99M CNY
Operating expenses	483.87M CNY	331.85M CNY	909.86M CNY	1.19B CNY	1.97B CNY
Interest income	10.12M CNY	12.67M CNY	24.89M CNY	9.67M CNY	9.8M CNY
Interest expense	12.93M CNY	15.17M CNY	11.82M CNY	8.48M CNY	2.24M CNY
Depreciation and amortization	11.98M CNY	18.93M CNY	58.19M CNY	44.54M CNY	22.66M CNY
Operating income	−432.62M CNY	−91.69M CNY	−605.57M CNY	−912.15M CNY	−1.83B CNY
Net income	−437M CNY	−91.21M CNY	−367.23M CNY	−902.68M CNY	−1.92B CNY